Aachen, Germany

Stefan Oberboersch

This inventor holds 35 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents, primarily in Spirocyclic Compounds. Top assignee: Gruenenthal Gmbh. Active years: 2007-2018.

USPTO Granted Patents = 35 

% Patents Active = 25.7


Average Co-Inventor Count = 7.5

ph-index = 9

Forward Citations = 191(Granted Patents)


Company Filing History:


Years Active: 2007-2018

Loading Chart...
Loading Chart...
Areas of Expertise:
Spirocyclic Compounds
Sulfonamide Compounds
Analgesic Activity
Tetrahydropyrrolopyrazine
Imidazoline Compounds
Cyclohexane Compounds
Pharmaceutical Compositions
Pain Treatment
Bicyclic Compounds
Oxazole Compounds
Opioid Receptor Ligands
Cyclohexylmethyl Compounds
35 patents (USPTO):Explore Patents

Title: Stefan Oberboersch - Innovative Inventor from Aachen

Introduction: Stefan Oberboersch is a renowned inventor based in Aachen, Germany, known for his groundbreaking contributions to various industries through his innovative creations.

Latest Patents: Stefan Oberboersch holds several recent patents in the fields of renewable energy, sustainable technology, and advanced manufacturing processes, showcasing his commitment to driving progress through innovation.

Career Highlights: With a career spanning over two decades, Stefan Oberboersch has established himself as a leading figure in the world of inventions, with a focus on developing solutions that address pressing global challenges.

Collaborations: Throughout his career, Stefan Oberboersch has collaborated with top research institutions, universities, and companies to bring his inventions to life, fostering a culture of innovation and excellence in the process.

Conclusion: Stefan Oberboersch's passion for innovation and his dedication to creating a positive impact on society make him a truly inspiring figure in the world of inventors, with a legacy that continues to shape the future of technology and beyond.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…